Related Experiment Video

Updated: Apr 5, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K

A Kinase Divided

Aroon S Karra1, Clinton A Taylor1, Curtis A Thorne1

  • 1Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Cancer Cell
|August 13, 2015
PubMed

Insights

Researchers discovered a small molecule that stops ERK protein dimerization, offering a new way to fight drug-resistant cancers by targeting protein interactions instead of just enzyme activity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Kinase signaling pathways, such as the ERK pathway, are crucial in cancer development and progression.
  • Drug resistance remains a significant challenge in cancer therapy, often linked to aberrant kinase signaling.
  • Targeting protein-protein interactions is an emerging strategy in drug development.

Purpose of the Study:

  • To identify novel therapeutic strategies for overcoming drug resistance in cancer.
  • To investigate the role of ERK dimerization in cancer signaling.
  • To evaluate a small molecule inhibitor targeting ERK dimerization.

Main Methods:

  • Utilized biochemical assays to assess the effect of a small molecule on ERK dimerization.
  • Investigated the molecule's impact on ERK catalytic activity and MEK-mediated phosphorylation.
  • Evaluated the anti-tumorigenic potential of the identified small molecule.

Main Results:

  • Identified a novel small molecule with anti-tumorigenic properties.
  • The small molecule specifically inhibits ERK dimerization without affecting its catalytic activity.
  • Demonstrated that MEK-mediated phosphorylation of ERK is independent of ERK dimerization.

Conclusions:

  • Targeting protein dimerization, specifically ERK dimerization, is a viable therapeutic strategy.
  • Inhibiting kinase signaling through protein-protein interaction blockade offers a promising approach to combat drug resistance.
  • This study opens new avenues for developing targeted cancer therapies.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.7K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

4.7K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.6K